Lethal pneumonitis after docetaxel chemotherapy: Case report and review of the literature

Storaas, Eivind; Holmaas, Gunhild; Gravdal, Karsten; Børretzen, Astrid; Eikesdal, Hans Petter

doi:10.3109/0284186x.2012.750734

Cited by 10 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Docetaxel, a taxane with activity against a wide range of cancers, has as its most common side effects myelosuppression, alopecia, neurotoxicity, and fluid retention. The rarest complication is pulmonary injury, of which about 30 cases have been reported in the literature to date (1–15), although Grande et al (6) affirmed that grade 3–4 toxicity may range from 7% to 47%. The exact mechanism by which docetaxel exerts a toxic effect on the lungs is not known: it is hypothesized that the drug induces proliferation of cytotoxic T cells against specific pulmonary antigens expressed by the tumor (2, 6).…”

Section: Discussionmentioning

confidence: 99%

A Commentary on Interstitial Pneumonitis Induced by Docetaxel: Clinical Cases and Systematic Review of the Literature

Genestreti¹,

M²,

Trisolini³

et al. 2015

Tumori

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A Commentary on Interstitial Pneumonitis Induced by Docetaxel: Clinical Cases and Systematic Review of the Literature

Genestreti¹,

M²,

Trisolini³

et al. 2015

Tumori

View full text Add to dashboard Cite

show abstract

“…However, weekly schedule of docetaxel reported lower incidence of myelosuppression when compared to triweekly schedule indicating that the incidence of pulmonary toxicity is more related to the delivery schedule of docetaxel rather than its dose [3,[8][9][10]. However, in our case, the patient developed pneumonitis despite the adoption of triweekly administration schedule of docetaxel thus a more keen monitoring of the patients should be conducted even if they are on a triweekly dosing schedule.…”

Section: Discussionmentioning

confidence: 62%

“…docetaxel 100 mg/m 2 and was found to be steroid resistant. The pneumonitis was worsened by other complications such as severe hypercapnia and hypoxia, bilateral pneumothorax, and reduced lung compliance because of which the patient died in the intensive care unit after 20 days of advanced ventilator supports [8].…”

Section: Discussionmentioning

confidence: 99%

Case Report on Docetaxel-Induced Interstitial Lung Disease

Antony

Krishna

James

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Docetaxel belongs to taxane family of antineoplastic agents that are indicated for the treatment of locally advanced or metastatic non-small-cell lung cancer. Docetaxel is associated with many adverse effects, and pulmonary reaction has an incidence of 41%. However, interstitial pulmonary disease is found to occur only in <1% of the population as per the post-marketing surveillance reports. Here, we report a case of docetaxel-induced interstitial lung disease (ILD). The patient information and details were collected using the hospital information system. The adverse drug reaction (ADR) of ILD occurred after 5 cycles of chemotherapy with docetaxel at a dose of 60 mg/m 2 that is 80 mg IV. The causality of the event in our case was assessed using the Naranjo ADR probability scale which marked a score of 7 (probable). It is necessary that all physicians be aware of the reaction and to closely monitor clinicoradiological and functional status of the patients at regular intervals after administration of docetaxel.

show abstract

“…En una serie japonesa de 392 pacientes con cáncer de pulmón de células no pequeñas se encontraron 18 episodios neumonitis para una incidencia global de 4,6% 4 . A pesar de su baja frecuencia esta complicación tiene un alto riesgo de muerte por lo que bien vale la pena conocerla; el 35% de los casos necesitan ventilación mecánica y la mortalidad general es de 42%, pero asciende al 82% en los pacientes que requieren intubación orotraqueal 5 .…”

Section: Discussionunclassified

Neumonitis por docetaxel, discusión de un caso

Ramírez

Mejía

Quiroga

2019

Rev. colomb. cancerol.

View full text Add to dashboard Cite

La neumonitis intersticial por docetaxel es un evento infrecuente, pero con alto potencial de mortalidad y puede ser potencialmente reversible con el uso de esteroides sistémicos; se considera importante en el diagnóstico diferencial del paciente bajo quimioterapia con síntomas respiratorios. A continuación, se presenta un caso de neumonitis fatal por docetaxel en un paciente con carcinoma de próstata avanzado. Paciente de 80 años de edad con historia de cáncer de próstata de 15 años de evolución, en progresión ósea y ganglionar, y que inició manejo con docetaxel. Después de la aplicación del tercer ciclo presenta disnea de esfuerzos, fiebre, tos seca y deterioro general. Se realizó diagnóstico de neumonitis por docetaxel y se descartaron otras entidades. La neumonitis intersticial por docetaxel es una entidad rara. Los pilares del tratamiento son la suspensión del medicamento, el soporte ventilatorio y el uso de glucocorticoides sistémicos.

show abstract

Lethal pneumonitis after docetaxel chemotherapy: Case report and review of the literature

Cited by 10 publications

References 19 publications

A Commentary on Interstitial Pneumonitis Induced by Docetaxel: Clinical Cases and Systematic Review of the Literature

A Commentary on Interstitial Pneumonitis Induced by Docetaxel: Clinical Cases and Systematic Review of the Literature

Case Report on Docetaxel-Induced Interstitial Lung Disease

Neumonitis por docetaxel, discusión de un caso

Contact Info

Product

Resources

About